Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
Kim GHJ, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, Khanna D, Elashoff RM, Tseng CH, Roth MD, Goldin JG. Kim GHJ, et al. Among authors: elashoff rm. Arthritis Rheumatol. 2020 Feb;72(2):316-325. doi: 10.1002/art.41085. Epub 2019 Dec 26. Arthritis Rheumatol. 2020. PMID: 31430058 Free PMC article.
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.
Volkmann ER, Tashkin DP, Roth MD, Li N, Charles J, Mayes M, Kim G, Goldin J, Pourzand L, Clements PJ, Furst DE, Khanna D, Elashoff RM, Assassi S. Volkmann ER, et al. Among authors: elashoff rm. Semin Arthritis Rheum. 2020 Oct;50(5):963-967. doi: 10.1016/j.semarthrit.2020.06.003. Epub 2020 Jun 16. Semin Arthritis Rheum. 2020. PMID: 32906032 Free PMC article. Clinical Trial.
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease.
Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; Scleroderma Lung Study Research Group. Goldin JG, et al. Among authors: elashoff rm. Chest. 2008 Aug;134(2):358-367. doi: 10.1378/chest.07-2444. Epub 2008 Jul 18. Chest. 2008. PMID: 18641099 Clinical Trial.
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S. Volkmann ER, et al. Among authors: elashoff rm. Arthritis Res Ther. 2016 Dec 30;18(1):305. doi: 10.1186/s13075-016-1203-y. Arthritis Res Ther. 2016. PMID: 28038680 Free PMC article. Clinical Trial.
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Volkmann ER, et al. Among authors: elashoff rm. Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23. Arthritis Rheumatol. 2017. PMID: 28376288 Free PMC article.
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups. Volkmann ER, et al. Among authors: elashoff rm. Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8. Ann Rheum Dis. 2019. PMID: 30409830 Free PMC article. Clinical Trial.
207 results